USD 0.36
(3.62%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 41.56 Million USD | 2.79% |
2022 | 40.43 Million USD | 30.38% |
2021 | 31.01 Million USD | 87.63% |
2020 | 16.53 Million USD | 140.02% |
2019 | 6.88 Million USD | 688699900.0% |
2018 | 1.00 USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | -100.0% |
2015 | 1.00 USD | 0.0% |
2014 | 1.00 USD | 0.0% |
2013 | - USD | -100.0% |
2012 | 1.00 USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 25.39 Million USD | -7.09% |
2024 Q1 | 27.33 Million USD | -34.24% |
2023 Q2 | 41.17 Million USD | -3.01% |
2023 Q4 | 41.56 Million USD | 2.14% |
2023 FY | 41.56 Million USD | 2.79% |
2023 Q1 | 42.45 Million USD | 5.0% |
2023 Q3 | 40.69 Million USD | -1.17% |
2022 Q1 | 43.06 Million USD | 38.86% |
2022 FY | 40.43 Million USD | 30.38% |
2022 Q4 | 40.43 Million USD | 1.22% |
2022 Q3 | 39.95 Million USD | -2.32% |
2022 Q2 | 40.89 Million USD | -5.03% |
2021 Q4 | 31.01 Million USD | 5.8% |
2021 Q2 | 24.53 Million USD | 18.14% |
2021 Q3 | 29.31 Million USD | 19.51% |
2021 FY | 31.01 Million USD | 87.63% |
2021 Q1 | 20.76 Million USD | 25.61% |
2020 Q4 | 16.53 Million USD | 40.05% |
2020 Q1 | 8.4 Million USD | 22.09% |
2020 Q2 | 8.58 Million USD | 2.07% |
2020 Q3 | 11.8 Million USD | 37.53% |
2020 FY | 16.53 Million USD | 140.02% |
2019 FY | 6.88 Million USD | 688699900.0% |
2019 Q4 | 6.88 Million USD | 40.32% |
2019 Q2 | 1.98 Million USD | 198099900.0% |
2019 Q1 | 1.00 USD | 0.0% |
2019 Q3 | 4.9 Million USD | 147.75% |
2018 Q1 | - USD | 0.0% |
2018 FY | 1.00 USD | 0.0% |
2018 Q4 | 1.00 USD | 0.0% |
2018 Q3 | - USD | -100.0% |
2018 Q2 | 1.00 USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q4 | - USD | -100.0% |
2017 Q3 | 1.00 USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2016 Q1 | - USD | -100.0% |
2016 FY | - USD | -100.0% |
2016 Q4 | - USD | 0.0% |
2016 Q3 | - USD | -100.0% |
2016 Q2 | 1.00 USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q1 | - USD | -100.0% |
2015 Q2 | - USD | 0.0% |
2015 FY | 1.00 USD | 0.0% |
2015 Q4 | 1.00 USD | 0.0% |
2014 Q4 | 1.00 USD | 0.0% |
2014 Q3 | 1.00 USD | 0.0% |
2014 Q2 | 1.00 USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 FY | 1.00 USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | - USD | -100.0% |
2012 FY | 1.00 USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Editas Medicine, Inc. | - USD | -Infinity% |
Dynavax Technologies Corporation | 53.29 Million USD | 22.002% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 46.304% |
Perrigo Company plc | 1.14 Billion USD | 96.357% |
Illumina, Inc. | 587 Million USD | 92.919% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.183% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | -300.742% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.5% |
IQVIA Holdings Inc. | - USD | -Infinity% |
Heron Therapeutics, Inc. | 42.11 Million USD | 1.294% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 98.389% |
Unity Biotechnology, Inc. | - USD | -Infinity% |
Waters Corporation | 516.23 Million USD | 91.948% |
Biogen Inc. | 2.52 Billion USD | 98.355% |
Sangamo Therapeutics, Inc. | - USD | -Infinity% |
Evolus, Inc. | 10.99 Million USD | -277.932% |
Adicet Bio, Inc. | - USD | -Infinity% |
Cara Therapeutics, Inc. | 2.82 Million USD | -1373.414% |
bluebird bio, Inc. | 22.91 Million USD | -81.356% |
Esperion Therapeutics, Inc. | 65.62 Million USD | 36.661% |
Agilent Technologies, Inc. | 1.03 Billion USD | 95.968% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Homology Medicines, Inc. | - USD | -Infinity% |
Geron Corporation | - USD | -Infinity% |
Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 53.374% |
Amicus Therapeutics, Inc. | 59.69 Million USD | 30.372% |
Myriad Genetics, Inc. | 20.1 Million USD | -106.791% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | - USD | -Infinity% |
Zoetis Inc. | 2.56 Billion USD | 98.379% |
Abeona Therapeutics Inc. | -2.44 Million USD | 1800.696% |
Mettler-Toledo International Inc. | 385.86 Million USD | 89.228% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 96.246% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 94.374% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -46.227% |
Atara Biotherapeutics, Inc. | 9.7 Million USD | -328.24% |
Verastem, Inc. | - USD | -Infinity% |
Nektar Therapeutics | 16.1 Million USD | -158.152% |
Axsome Therapeutics, Inc. | 15.13 Million USD | -174.628% |
Aclaris Therapeutics, Inc. | - USD | -Infinity% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 87.126% |
OPKO Health, Inc. | 65.69 Million USD | 36.732% |
Exelixis, Inc. | 17.32 Million USD | -139.941% |
Neurocrine Biosciences, Inc. | 38.3 Million USD | -8.525% |
Corcept Therapeutics Incorporated | 7.73 Million USD | -437.71% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 12.02 Million USD | -245.684% |
Imunon, Inc. | - USD | -Infinity% |
Blueprint Medicines Corporation | 21.22 Million USD | -95.849% |
Insmed Incorporated | 83.24 Million USD | 50.071% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 67.426% |
Agios Pharmaceuticals, Inc. | 19.07 Million USD | -117.892% |
TG Therapeutics, Inc. | 39.82 Million USD | -4.374% |
Incyte Corporation | 62.97 Million USD | 33.994% |
Emergent BioSolutions Inc. | 328.9 Million USD | 87.362% |